Timing Is Crucial: Sooner Is Better for Rectal Cancer Surgery Timing Is Crucial: Sooner Is Better for Rectal Cancer Surgery
Survival outcomes are considerably better for patients with rectal cancer who have surgery within 8 weeks or less after not responding to neoadjuvant chemoradiation.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 7, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Virtual Symposium to Focus on Mesothelioma Treatment Advances
Sylvester Comprehensive Cancer Center of South Florida will host its free virtual First Miami International Mesothelioma Symposium on November 6, 2021. The Mesothelioma Program at the Sylvester Comprehensive Cancer Center has grown to become one of America’s leaders in this specialized field, attracting a wide range of expertise for its upcoming virtual symposium. “Mesothelioma is such a rare disease that we really have to bring in experts from around the world to get a true picture of what’s coming next. And I think we’ve done that with our program,” medical oncologist Dr. Estelamari Ro...
Source: Asbestos and Mesothelioma News - October 5, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

BrighTNess Follow-Up Data Shed Light on TNBC Therapy BrighTNess Follow-Up Data Shed Light on TNBC Therapy
Patients with triple negative breast cancer had improved event-free survival when carboplatin (but not the PARP inhibitor veliparib) was added to standard neoadjuvant chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral present...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mesothelioma Research, COVID Findings Featured at IASLC Conference
This study, performed during the pre-vaccine period of the pandemic, once again demonstrates the importance of vaccination against COVID-19,” said Dr. Susana Cedres, a medical oncologist with Vall d’Hebron Hospital. “Malignant pleural mesothelioma patients are particularly vulnerable to COVID-19.” Cedres said since the subsequent rollout of the COVID-19 vaccines, no positive cases have been attributed to pleural mesothelioma patients at the hospital. The average age of the seven patients was 62. All had the epithelioid histology of mesothelioma and two were receiving oncologic treatment at the...
Source: Asbestos and Mesothelioma News - September 15, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Chemotherapy Induced Immune Microenvironment Changes in TNBC Chemotherapy Induced Immune Microenvironment Changes in TNBC
A better understanding of the impacts of neoadjuvant chemotherapy on the immune microenvironment could have important prognostic implications in triple-negative breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Duke Study Suggests Radiation Does Not Extend Mesothelioma Survival
A dual registry analysis by the esteemed Duke University Medical Center has concluded that adjuvant hemithoracic radiation does not improve survival when combined with aggressive surgery for patients with malignant pleural mesothelioma. Although the U.S. National Comprehensive Cancer Network and the European Society for Medical Oncology recommend the adjuvant radiation – as do many specialists – the Duke research team has challenged the conventional treatment with this report. “The receipt of adjuvant hemithoracic radiation was not associated with improved survival when compared to no radiation,&rdq...
Source: Asbestos and Mesothelioma News - August 9, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Neoadjuvant Chemoimmunotherapy in Resectable NSCLC Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
Is the use of neoadjuvant immunotherapy combined with chemotherapy a safe and effective therapeutic option for patients with resectable non-small cell lung cancer?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

FDA Approves Neoadjuvant Pembro for Triple-Negative Breast Cancer FDA Approves Neoadjuvant Pembro for Triple-Negative Breast Cancer
The approval is based on phase 3 trial data showing prolonged event-free survival with the pembrolizumab regimen vs neoadjuvant chemotherapy alone for previously untreated stage II or III TNBC.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 28, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Keytruda (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
KENILWORTH, N.J.--(BUSINESS WIRE) July 27, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 27, 2021 Category: Drugs & Pharmacology Source Type: news

Top Abstracts in Locally Advanced NSCLC From ASCO 2021 Top Abstracts in Locally Advanced NSCLC From ASCO 2021
Dr Thomas Stinchcombe discusses key data on locally advanced NSCLC from ASCO 2021, including results of atezolizumab as adjuvant therapy and chemotherapy plus immunotherapy in the neoadjuvant setting.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 29, 2021 Category: Consumer Health News Tags: None ReCAP Source Type: news

For Residual TNBC Post-Chemo, Capecitabine Should Be Offered For Residual TNBC Post-Chemo, Capecitabine Should Be Offered
For high-risk patients with triple-negative breast cancer who have residual disease following neoadjuvant therapy, Dr Kathy Miller says we must accept capecitabine as the standard of care.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Long-Term ERLEADA ® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of lif...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Opdivo (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy
PRINCETON, N.J.--(BUSINESS WIRE) May 20, 2021 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab, injection for intravenous use) for the adjuvant treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 20, 2021 Category: Drugs & Pharmacology Source Type: news

U.S. FDA Approves Opdivo (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy
PRINCETON, N.J.--(BUSINESS WIRE) May 20, 2021 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab, injection for intravenous use) for the adjuvant treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 20, 2021 Category: Drugs & Pharmacology Source Type: news

Impact of Tumor Size on pCR Rates in TNBC After Chemotherapy Impact of Tumor Size on pCR Rates in TNBC After Chemotherapy
What impact might tumor size have on pathological complete response rates in triple negative breast cancer patients receiving neoadjuvant chemotherapy?Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

BERENICE: Further Evidence of Heart Safety of Dual HER2 Blockade BERENICE: Further Evidence of Heart Safety of Dual HER2 Blockade
Final results were presented at ESMO Breast Cancer 2021 on dual HER2 blockade with pertuzumab and trastuzumab on top of anthracycline-based neoadjuvant chemotherapy for early-stage breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Media News - April 27, 2021 Category: Pharmaceuticals Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Investor Update - April 27, 2021 Category: Pharmaceuticals Source Type: news

Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); ho...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Adjuvant Nivolumab Beneficial in Esophageal, GE Junction Cancer
THURSDAY, April 1, 2021 -- Among patients with resected esophageal or gastroesophageal junction cancer who have received neoadjuvant chemoradiotherapy, disease-free survival is significantly longer with nivolumab adjuvant therapy versus placebo,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 1, 2021 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Media News - March 26, 2021 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Investor Update - March 26, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news

Age Should Not Prevent Aggressive Esophageal Cancer Treatment Age Should Not Prevent Aggressive Esophageal Cancer Treatment
Neoadjuvant chemoradiation plus esophagectomy can be performed safely in well-selected older patients with locally advanced esophageal or esophagogastric junction cancer, according to a reviewMedscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 2, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Optimal Therapy for Esophageal Cancer Feasible in Fit Elderly
FRIDAY, Feb. 26, 2021 -- Patients 70 years and older with locally advanced esophageal or esophagogastric junction (EGJ) cancer should be considered for optimal, potentially curative therapy, including neoadjuvant chemoradiotherapy and surgical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 26, 2021 Category: Pharmaceuticals Source Type: news

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cance...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo a...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Higher Intensity Therapy and Surgical Risk in Esophageal Cancer Higher Intensity Therapy and Surgical Risk in Esophageal Cancer
Combining standard neoadjuvant chemotherapy for locally advanced esophageal cancer with either radiation or docetaxel did not increase the risk of surgical complications, investigators in the JCOG1109 trial reported.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Early Breast Cancer Highlights From SABCS 2020 Early Breast Cancer Highlights From SABCS 2020
Highlights in early breast cancer from SABCS 2020 include data indicating that more HR+ women can skip adjuvant chemotherapy, and neoadjuvant atezolizumab does not worsen quality of life in early TNBC.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 31, 2020 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

European Commission approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.“This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo...
Source: Roche Investor Update - December 23, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer
Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.“This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo...
Source: Roche Media News - December 23, 2020 Category: Pharmaceuticals Source Type: news

Immediate Breast Reconstruction Feasible Following Neoadjuvant Chemo Immediate Breast Reconstruction Feasible Following Neoadjuvant Chemo
Long-term oncologic outcomes following neoadjuvant chemotherapy for breast cancer are similar with immediate breast reconstruction and conventional mastectomy alone, regardless of response to chemo, according to a retrospective study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 27, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

' Watch and Wait' Feasible for Some Rectal Cancer Patients
TUESDAY, Nov. 3, 2020 -- A " watch-and-wait " (WW) strategy may be an option for carefully selected patients who achieve a complete response (CR) to neoadjuvant chemoradiation (nCRT) for rectal adenocarcinoma, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 3, 2020 Category: Pharmaceuticals Source Type: news

Oncotarget: quantitative ultrasound radiomics in prediction of treatment response for breast cancer
(Impact Journals LLC) The cover for Issue 42 ofOncotarget features Figure 4, " Generation of parametric and texture maps from radiofrequency data, " recently published in " Quantitative ultrasound radiomics using texture derivatives in prediction of treatment response to neo-adjuvant chemotherapy for locally advanced breast cancer " by Dasgupta, et al. which reported that to investigate quantitative ultrasound based higher-order texture derivatives in predicting the response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 21, 2020 Category: International Medicine & Public Health Source Type: news

Image-Guided Biopsy May Help Some Avoid Breast Cancer Surgery Image-Guided Biopsy May Help Some Avoid Breast Cancer Surgery
Following neoadjuvant chemotherapy, image-guided vacuum-assisted biopsy (VAB) can reliably identify a subgroup of patients with no residual disease in the breast, according to an analysis of pooled data drawn from three continents.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 20, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Dual checkpoint blockade promising as pre-surgical approach for certain patients with localized bladder cancer
(University of Texas M. D. Anderson Cancer Center) Phase I trial finds neoadjuvant combination checkpoint inhibitors (anti-CTLA-4 plus anti-PD-1) was well tolerated and showed early signs of activity in certain patients with bladder cancer. These patients cannot be treated with chemotherapy and have no standard treatment options available. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 12, 2020 Category: Cancer & Oncology Source Type: news

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address...
Source: Roche Investor Update - September 19, 2020 Category: Pharmaceuticals Source Type: news

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address...
Source: Roche Media News - September 19, 2020 Category: Pharmaceuticals Source Type: news

Neoadjuvant Chemoradiotherapy Best Restricted to High-Risk Rectal Cancer Patients Neoadjuvant Chemoradiotherapy Best Restricted to High-Risk Rectal Cancer Patients
Because neoadjuvant chemoradiotherapy in patients with rectal cancer carries a high risk of adverse effects, careful selection is needed to avoid possibly harmful treatment, according to new research.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 3, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Pathological regression of lymph nodes better predicts esophageal cancer survival
(Osaka University) A team of researchers led by Osaka University established a new pathological grading system to evaluate the therapeutic effect of neoadjuvant chemotherapy (NAC) for metastatic lymph nodes (LNs) removed in esophageal cancer (EC) surgery, demonstrating that the system predicts recurrence and prognosis in EC patients better than conventional systems. Their findings will enable 'tailor-made' treatment according to the pathological assessment of all metastatic LNs, eventually improving treatment performance of EC. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 27, 2020 Category: International Medicine & Public Health Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Media News - July 13, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
             Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC i...
Source: Roche Investor Update - June 29, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
             Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC i...
Source: Roche Media News - June 29, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer
Basel, 18 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion031 study, evaluating Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chem otherapy (including Abraxane), met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early triple-negative breast cancer (TNBC), regardless of PD-L1 expression.“Tripl...
Source: Roche Media News - June 18, 2020 Category: Pharmaceuticals Source Type: news

ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th. ERLEADA® ...
Source: Johnson and Johnson - May 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news